| pubmed-article:1963300 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1963300 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:1963300 | lifeskim:mentions | umls-concept:C0027950 | lld:lifeskim |
| pubmed-article:1963300 | lifeskim:mentions | umls-concept:C0021745 | lld:lifeskim |
| pubmed-article:1963300 | lifeskim:mentions | umls-concept:C0038836 | lld:lifeskim |
| pubmed-article:1963300 | lifeskim:mentions | umls-concept:C0218986 | lld:lifeskim |
| pubmed-article:1963300 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1963300 | lifeskim:mentions | umls-concept:C0033268 | lld:lifeskim |
| pubmed-article:1963300 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:1963300 | pubmed:dateCreated | 1991-4-2 | lld:pubmed |
| pubmed-article:1963300 | pubmed:abstractText | The effect of recombinant human interleukin-2 (rhIL-2) and recombinant human interferon-gamma (rhIFN-gamma) were evaluated on superoxide (O2-) production of human polymorphonuclear neutrophils (PMNs). Ten minutes incubation with rhIL-2 showed a dose-dependent enhancement of n-formyl-methionyl-leucyl-phenylalanine (FMLP)-induced O2-production of human PMNs, and the rate of enhancement reached 49.6% at the concentration of 3000 U/ml rhIL-2. Same pretreatment with rhIFN-gamma also showed a dose-dependent enhancement of FMLP-induced O2-production of human PMNs, and the maximal rate of enhancement was 47.0% at the concentration of 3000 U/ml rhIFN-gamma. Any cytokines given alone did not induce O2- production. These cytokines showed no enhancement of phorbol myristate acetate (PMA)-induced O2- production, neither. The effects of these cytokines to FMLP-induced O2- production were kept in calcium-free medium. Moreover, incubation with these cytokines caused no elevation of intracellular free calcium concentration [( Ca++]i) in resting PMNs. Incubation with them did not change the increase of [( Ca++]i) of PMNs induced by FMLP significantly, neither. Recombinant forms of cytokines are used clinically, now. These results may be helpful for the use of them. | lld:pubmed |
| pubmed-article:1963300 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1963300 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1963300 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1963300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1963300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1963300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1963300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1963300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1963300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1963300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1963300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1963300 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1963300 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:1963300 | pubmed:issn | 0004-4172 | lld:pubmed |
| pubmed-article:1963300 | pubmed:author | pubmed-author:SuzukiKK | lld:pubmed |
| pubmed-article:1963300 | pubmed:author | pubmed-author:TakagiKK | lld:pubmed |
| pubmed-article:1963300 | pubmed:author | pubmed-author:KanekoMM | lld:pubmed |
| pubmed-article:1963300 | pubmed:author | pubmed-author:SatakeTT | lld:pubmed |
| pubmed-article:1963300 | pubmed:author | pubmed-author:FuruiHH | lld:pubmed |
| pubmed-article:1963300 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1963300 | pubmed:volume | 40 | lld:pubmed |
| pubmed-article:1963300 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1963300 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1963300 | pubmed:pagination | 1176-9 | lld:pubmed |
| pubmed-article:1963300 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:1963300 | pubmed:meshHeading | pubmed-meshheading:1963300-... | lld:pubmed |
| pubmed-article:1963300 | pubmed:meshHeading | pubmed-meshheading:1963300-... | lld:pubmed |
| pubmed-article:1963300 | pubmed:meshHeading | pubmed-meshheading:1963300-... | lld:pubmed |
| pubmed-article:1963300 | pubmed:meshHeading | pubmed-meshheading:1963300-... | lld:pubmed |
| pubmed-article:1963300 | pubmed:meshHeading | pubmed-meshheading:1963300-... | lld:pubmed |
| pubmed-article:1963300 | pubmed:meshHeading | pubmed-meshheading:1963300-... | lld:pubmed |
| pubmed-article:1963300 | pubmed:meshHeading | pubmed-meshheading:1963300-... | lld:pubmed |
| pubmed-article:1963300 | pubmed:meshHeading | pubmed-meshheading:1963300-... | lld:pubmed |
| pubmed-article:1963300 | pubmed:meshHeading | pubmed-meshheading:1963300-... | lld:pubmed |
| pubmed-article:1963300 | pubmed:meshHeading | pubmed-meshheading:1963300-... | lld:pubmed |
| pubmed-article:1963300 | pubmed:meshHeading | pubmed-meshheading:1963300-... | lld:pubmed |
| pubmed-article:1963300 | pubmed:meshHeading | pubmed-meshheading:1963300-... | lld:pubmed |
| pubmed-article:1963300 | pubmed:meshHeading | pubmed-meshheading:1963300-... | lld:pubmed |
| pubmed-article:1963300 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:1963300 | pubmed:articleTitle | Priming effect of recombinant human interleukin-2 and recombinant human interferon-gamma on human neutrophil superoxide production. | lld:pubmed |
| pubmed-article:1963300 | pubmed:affiliation | Second Department of Internal Medicine, School of Medicine, University of Nagoya, Japan. | lld:pubmed |
| pubmed-article:1963300 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1963300 | pubmed:publicationType | In Vitro | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1963300 | lld:pubmed |
